Comparison of Two Forms of Asparaginase in Treating Children With Previously Untreated Acute Lymphoblastic Leukemia

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Alternate Title

Phase II Randomized Pilot Study of Pegaspargase vs Native E. coli Asparaginase in the Standard Treatment Arm of Protocol CCG-1952 for Standard-Risk Acute Lymphoblastic Leukemia

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentClosed1 to 9NCICCG-1962

Trial Description


Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving drugs in different forms may cause fewer side effects in children with acute lymphoblastic leukemia.

Randomized phase II trial to compare the effectiveness and safety of two forms of asparaginase in treating children with previously untreated acute lymphoblastic leukemia.


Final eligibility for a clinical trial is determined by the health professionals conducting the trial.


Patients will be randomized to receive extended combination chemotherapy that includes either pegaspargase or asparaginase. Treatment may continue as long as benefit is shown, for up to 2 more years in girls and for up to 3 more years in boys. Patients will receive follow-up evaluations every 6-8 weeks for 1 year, every 3 months for 1 year, every 6 months for 1 year, and annually thereafter.


For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Children's Cancer Group

John Holcenberg, MD, Protocol chair
Ph: 206-987-2106